Phase 2 trial shows significant improvements in Pitt Hopkins
Filed with ASX · · 7 pages · English
Neuren Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Neuren Pharmaceuticals
- DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m
- Q1 2024 quarterly activity and cash flow report
- Trofinetide accepted for Priority Review by Health Canada
- Neuren reports profit of $157 million for 2023
- Appendix 4E and 2023 full year accounts
Later from Neuren Pharmaceuticals
- Q2 2024 update
- Phase 2 trial shows significant improvements in Angelman
- NEU continues PMS P3 preparations after positive FDA meeting
- DAYBUE receives marketing authorization in Canada
- PRV sold for US$150m - Neuren to receive one third
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals